Adaptimmune Limited

Designing and delivering cell therapies to transform the lives of people with cancer

With a research base in Milton Park, Oxfordshire, UK and a clinical base in Philadelphia, US, Adaptimmune is focused on the use of T cell therapy to treat cancer. It aims to utilise the body’s own machinery – the T cell – to target and destroy cancerous by using engineered, increased affinity T cell receptors (TCRs) as a means of strengthening natural patient T cell responses.